Study summary

Two-thirds of people stepped down and then stopped their pill and stayed in remission

Nilotinib de-escalation study · 107 people, phase 2 · Published September 2025, Hematological Oncology

What was tested

Halving the nilotinib dose for a year, then stopping it entirely, in people who had been in deep molecular remission for at least a year after 3 or more years of nilotinib.

What they found

• 84.1% were able to stop the pill after the step-down year.
• At 96 weeks, 66.4% of everyone who started were off treatment and still in remission.

What it means

Adds to evidence that many people with CML can stop lifelong pills safely under close monitoring.